We have now developed two OPN monoclonal antibodies (100D3 and 103D6) that are effective in enhancing tumor-specific CTL lytic activity in killing colon tumor cells and in suppressing colon tumor growth in vivo. Here, SPP1 is linked to colonic neoplasm.